Warfarin Dosing: Pharmacogenetic Algorithm Compared to Pharmacist's Dosing
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Atrial Fibrillation
- Sponsor
- Creighton University
- Enrollment
- 102
- Primary Endpoint
- In Patients Receiving Warfarin, a Pharmacogenetic Algorithm Dose Was Compared to Clinician Dosing (mg/wk).
- Status
- Completed
- Last Updated
- 13 years ago
Overview
Brief Summary
This is a prospective comparison of clinician dosing and a pharmacogenetic algorithm in diagnosed patients requiring warfarin therapy.
Detailed Description
Diagnosed patients with atrial fibrillation, pulmonary embolism, or deep venous thrombosis requiring warfarin therapy will be consented and a tube of blood for DNA analysis will be drawn. The clinician dosing group will not be eligible to obtain the pharmacogenetic results and the algorithm group will have their warfarin pharmacogenetic SNPs performed and integrated into the algorithm and the warfarin dose will be calculated. Outcomes of patients receiving both methods will be gathered and statistically analyzed.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Diagnosed patients with atrial fibrillation, deep venous thrombosis, or pulmonary embolism requiring warfarin therapy
Exclusion Criteria
- •Patients with atrial fibrillation, deep venous thrombosis, or pullmonary embolism requiring warfarin therapy who do not consent to participate
Outcomes
Primary Outcomes
In Patients Receiving Warfarin, a Pharmacogenetic Algorithm Dose Was Compared to Clinician Dosing (mg/wk).
Time Frame: six months
Warfarin pharmacogenetic algorithm dosing (mg/wk) was compared to clinician warfarin dosing (mg/wk).